PHVS

Pharvaris N.V. [PHVS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PHVS Stock Summary

In the News

PHVS Financial details

Company Rating
-
Market Cap
894.76M
Income
-84.69M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
70
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-11.31
Forward P/E
-
PEG
-0.98
P/S
-
P/B
6.26
P/C
-
P/FCF
-10.66
Quick Ratio
9.85
Current Ratio
10.46
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.04
EPS next Y
-
EPS next Q
-
EPS this Y
60.99%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-7.94%
-
-
-
-
SMA20
3.33%
SMA50
10.71%
SMA100
19.23%
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
-56%
ROC
-0.48%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.93-33.0
52W High
-6.09%
52W Low
+342.71%
RSI
55
Rel Volume
1.2
Avg Volume
110.2K
Volume
131.75K
Perf Week
-2.02%
Perf Month
5.26%
Perf Quarter
21.1%
Perf Half Y
28.91%
-
-
-
-
Beta
-3.113
-
-
Volatility
0.44%, 1.04%
Prev Close
-3.76%
Price
30.9898
Change
-1.82%

Something similar

Top by Market Cap
NVD.DE
VTI
NVDA
TSLA
AMZ.DE
Same Sector
WINT
3544.T
603880.SS
6547.TWO
600385.SS
Same Price Range
CRZY
PQDI
SILXY
COK.DE
SAOCX
Similar Market Cap
CII
0QU6.L
0658.HK
IPRA.AS
SCWX

Company Profile

Healthcare Biotechnology
  • Volume Average 110.2K
  • Market Capitalization 894.76M
  • Employee 70
  • CEO Mr. Berndt Axel Edvard Modig CPA, M.B.A.
  • Headquarters Leiden,NL
  • IPO Date 2021-02-05
  • Website https://pharvaris.com

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.